Lyell Immunopharma, Inc. (LYEL) stock
LYELNasdaqPharmaceutical PreparationsFiscal year ends December 31
$13.67−0.98 (-6.69%)
Close on Nov 17, 2026Market cap $334.99MP/E –Yield –
Lyell Immunopharma total assets
Total assets on the balance sheet at the end of each period.
Lyell Immunopharma's total assets was $311.15M at Jun 30, 2026. For fiscal 2025 it was $340.05M, down 30.7% from the year before. The highest annual figure on record is $1.13B in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $340.05M | -30.7% |
| FY2024 | Dec 31, 2024 | $490.86M | -34.6% |
| FY2023 | Dec 31, 2023 | $750.03M | -20.0% |
| FY2022 | Dec 31, 2022 | $937.56M | -16.8% |
| FY2021 | Dec 31, 2021 | $1.13B | +24.1% |
| FY2020 | Dec 31, 2020 | $908.28M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $311.15M | -19.3% |
| Q1 FY2026 | Mar 31, 2026 | $350.63M | -18.4% |
| Q4 FY2025 | Dec 31, 2025 | $340.05M | -30.7% |
| Q3 FY2025 | Sep 30, 2025 | $407.97M | -34.1% |
| Q2 FY2025 | Jun 30, 2025 | $385.45M | -41.1% |
| Q1 FY2025 | Mar 31, 2025 | $429.80M | -38.1% |
| Q4 FY2024 | Dec 31, 2024 | $490.86M | -34.6% |
| Q3 FY2024 | Sep 30, 2024 | $619.22M | -22.1% |
| Q2 FY2024 | Jun 30, 2024 | $654.14M | -21.7% |
| Q1 FY2024 | Mar 31, 2024 | $694.22M | -21.2% |
| Q4 FY2023 | Dec 31, 2023 | $750.03M | -20.0% |
| Q3 FY2023 | Sep 30, 2023 | $794.99M | -18.7% |
| Q2 FY2023 | Jun 30, 2023 | $835.35M | -18.2% |
| Q1 FY2023 | Mar 31, 2023 | $880.45M | -17.9% |
| Q4 FY2022 | Dec 31, 2022 | $937.56M | -16.8% |
| Q3 FY2022 | Sep 30, 2022 | $977.27M | -18.4% |
| Q2 FY2022 | Jun 30, 2022 | $1.02B | -16.9% |
| Q1 FY2022 | Mar 31, 2022 | $1.07B | +18.0% |
| Q4 FY2021 | Dec 31, 2021 | $1.13B | – |
| Q3 FY2021 | Sep 30, 2021 | $1.20B | – |
| Q2 FY2021 | Jun 30, 2021 | $1.23B | – |
| Q4 FY2020 | Dec 31, 2020 | $908.28M | – |
See a number that looks wrong?